How to Properly Document Adverse Events in Source Records During Clinical Trials

In clinical trials, every reported Adverse Event (AE) must be backed by accurate and verifiable source documentation. Proper AE documentation ensures the integrity of safety data, facilitates sponsor and regulatory review, and supports Good Clinical Practice (GCP) compliance. This guide walks clinical professionals through the standards and best practices for documenting AEs in source documents effectively.

What Is Source Documentation?

According to ICH GCP, source documents are the original records that capture clinical trial data and findings. For adverse events, these may include:

• Physician or nurse progress notes
• Electronic Medical Records (EMRs)
• Hospital discharge summaries
• Telephone contact logs
• Patient diaries (when validated as source)

Source documentation must allow verification of AE date, severity, seriousness, duration, and resolution.

Why AE Source Documentation Matters:

• Ensures that AEs are accurately reported in the CRF/EDC
• Supports USFDA and EMA regulatory audits
• Enables causality assessments by the investigator
• Allows effective safety signal detection and analysis
• Prevents protocol deviations due to inconsistent reporting

Best Practices for AE Source Documentation:

1. Consistency with CRF/EDC:

• Ensure all AEs entered in CRFs are traceable to source records
• Verify dates, descriptions, and severity match exactly
• Use the same terminology across systems

2. Real-Time Entry:

• Document AEs in source records as soon as they are identified
• Back-date entries only if clearly indicated and justified
• Use version control in EMR if edits are made

3. Level of Detail:

• Include onset date, resolution date, description, and action taken
• Record severity (mild, moderate, severe) and seriousness criteria
• Note investigator’s assessment of causality

4. Traceability and Clarity:

• Clearly identify AE-related notes (label as “AE noted” or “SAE event”)
• Avoid ambiguous entries like “unwell” or “patient feels bad”
• Ensure all AE references are dated and signed by the investigator

Acceptable Source Formats:

• Handwritten site notes on subject chart (signed and dated)
• EMR printouts or screenshots with patient ID masked
• Validated AE tracking logs
• Certified translations for foreign documents

Refer to Pharma SOP documentation for source verification procedures.

Red Flags in AE Documentation:

• AEs recorded in EDC but absent in source
• Back-dated AE entries without reason
• Source note missing AE resolution date
• Conflicting information between EMR and site file
• Handwritten notes lacking investigator signature

Step-by-Step Guide for AE Source Documentation:

1. Detect AE: Patient reports symptom, or AE noted in vitals, labs, or physical exam
2. Record in Source: Create dated entry in source note or EMR including description, severity, and related action
3. Assess and Document Causality: Investigator evaluates relation to IP and notes judgment
4. Update with Follow-up: Add resolution or outcome once known
5. Transcribe to EDC: Enter the AE in CRF or EDC with identical details

Common Scenarios and Examples:

Example 1: Mild Rash

Patient reports skin rash 3 days post-dose. Source note should include: “Subject developed mild erythematous rash on arms on Day 3. No medication given. Resolved by Day 5. Investigator assessment: not related to IP.”

Example 2: Hospitalization

Subject admitted for dehydration. Include admission/discharge summaries, site note with seriousness criteria, and outcome assessment.

Example 3: Lab Value Deviation

High ALT detected. Source note: “ALT 3x ULN noted on Day 12. No symptoms. Event classified as AE of increased transaminase. No action taken. ALT normalized by Day 19.”

Regulatory Considerations:

As per ICH GCP and CDSCO requirements:

• Every AE must be traceable to a documented source
• Incomplete or missing source records may be flagged in audits
• Consistency checks are performed during monitoring and data validation

Tips to Improve AE Documentation Compliance:

• Use AE stamps or templates to guide documentation
• Train site staff to document before CRF entry
• Align site templates with GMP compliance requirements
• Incorporate AE checklists during each patient visit
• Audit AE notes quarterly to detect discrepancies

Final Checklist for AE Source Documentation:

• [ ] AE description is clear and medical
• [ ] Onset and resolution dates included
• [ ] Severity and seriousness recorded
• [ ] Causality judgment noted
• [ ] Action taken and outcome documented
• [ ] Investigator signed and dated
• [ ] AE linked to corresponding CRF entry

Conclusion:

Robust source documentation of AEs is critical for data credibility, safety review, and regulatory readiness in clinical trials. By maintaining consistency, clarity, and completeness in your records, you ensure both scientific integrity and participant protection. Make AE documentation a routine yet meticulous practice at your trial site.